Hendrik W. Reesink

TL;DR: The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance.

TL;DR: Therapy with sofosbuvir-ribavirin for 12 weeks in patients with hepatitis C virus genotype 2 infection and for 24 weeks in Patients with HCV genotype 3 infection resulted in high rates of sustained virologic response.

TL;DR: Among patients with chronic HCV infection who had not received treatment previously, a regimen of peginterferon-ribavirin for 24 weeks, with telaprevir for the first 12 weeks, was noninferior to the same regimen for 48 weeks in patients with undetectable HCV RNA at weeks 4 and 12, with an extended rapid virologic response achieved in nearly two thirds of patients.

TL;DR: In HCV-infected patients in whom initial peginterferon alfa-2a and ribavirin treatment failed, retreatment with telaprevir in combination with pegin terferonAlfa-1a and 2a and Ribavirin was more effective than retreatment without combination.

TL;DR: VX-950 was well tolerated and demonstrated substantial antiviral activity in patients with chronic hepatitis C, and some patients had viral breakthrough during dosing, related to selection of variants with decreased sensitivity to VX- 950.